尼亚通过维持肠道平衡和调节HCAR2/NLRP3和PTGS2/PGE2信号通路来缓解环胺诱导的免疫抑制
Yixian Bai1, Yifan Zhou2, Guifa Wang3
1Department of Nutrition and Food Hygiene, School of Public Health, Qingdao University, 308 Ningxia Road, Qingdao 266071, China.
Nutrients
|March 14, 2026
概括
氨酸补充剂通过维持肠道健康和调节关键炎症通路,包括HCAR2/NLRP3和PTGS2/PGE2.2,从而提高免疫功能.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫抑制,通常由化疗诱导,损害免疫防御和肠道平衡.
- 氨酸 (维生素B3) 在各种生理过程中发挥作用,但其在受损状态下的免疫调节作用需要进一步阐明.
- 肠道屏障完整性和特定的信号通路,如HCAR2/NLRP3和PTGS2/PGE2,都与免疫调节有关.
研究的目的:
- 调查尼亚补充剂是否可以恢复循环胺 (CTX) 诱导的免疫抑制小鼠的免疫功能.
- 确定肠道平衡和HCAR2/NLRP3和PTGS2/PGE2信号通路在尼亚免疫调节作用中的作用.
- 为了确定氨酸在抵消免疫抑制方面潜在的分子标.
主要方法:
- Balb/c小鼠使用环胺 (CTX) 进行免疫抑制.
- 补充了尼亚,并评估了免疫参数 (脏/肝脏指数,细胞因子,NK细胞活性,DTH).
- 分析了肠道屏障功能,肠道微生物组成以及关键信号通路表达 (HCAR2/NLRP3,PTGS2/PGE2).
- 网络药理学被用来识别尼亚的分子标.
主要成果:
- 尼亚恢复了脏和肝脏指数,增强了细胞因子分泌,并改善了CTX治疗小鼠的免疫细胞活性.
- 肠道损伤得到缓解,紧结蛋白表达得到改善,屏障功能障碍 (DAO,FABP2) 的血清标志物减少.
- 尼亚调节了HCAR2/NLRP3和PTGS2/PGE2通路,降低了PTGS2,PGE2,EP2和EP4的表达,并增加了肠道微生物群F/B比率.
结论:
- 尼亚补充剂有效地减轻CTX诱导的免疫抑制在小鼠.
- 维持肠道平衡和调节HCAR2/NLRP3和PTGS2/PGE2通路是尼亚作用的关键机制.
- 尼亚显示出作为辅助疗法的潜力,可以在免疫抑制期间支持免疫功能.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
637
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
637
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
56
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
56
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
715
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
595
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
595
Drugs for Treatment of Ulcerative Colitis in IBD
591
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
591


